The 2019 European Society of Cardiology (ESC) lipid guidelines already recommend using apolipoprotein B (apoB) as an evaluation marker in obese people or in the case of combined hyperlipidemia and/or diabetes [5]. This evidence concerns the gene APOB and hyperlipidemia.